N/A
Completed N=720
Building on Needle Exchange to Optimize Prevention & Treatment
Intravenous Drug Usage · HIV
Source: ClinicalTrials.gov NCT03567174 ↗
Enrolled (actual)
720
Serious AEs
7.6%
Results posted
Dec 2022
Primary outcomePrimary: Composite PWID Score (Service Access, Risk Behaviors, Adverse Outcomes) — 5.34; 5.64 units on a scale — p=0.125
Summary
There are several biomedical interventions that can help people who inject drugs (particularly those with or at risk for HIV), but these services often do not get to the people most in need. In this project investigators propose to determine if delivery of these services to PWID by an integrated care van that is linked to a mobile syringe service program improves clinical outcomes, is feasible and sustainable, and is cost-effective.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Composite PWID Score (Service Access, Risk Behaviors, Adverse Outcomes) |
5.34; 5.64 | 0.125 |
| SECONDARY HIV Care Continuum |
13; 19; 18; 10; 1; 4 | — |
| SECONDARY HIV Testing |
234; 202; 2; 8 | — |
| SECONDARY Pre-exposure Prophylaxis (PrEP) Continuum |
0; 4; 236; 206 | — |
| SECONDARY HCV Care Continuum |
34; 20; 36; 25; 75; 58 | — |
| SECONDARY HCV Testing |
65; 66; 57; 73 | — |
| SECONDARY Medication for Opioid Use Disorder (MOUD) Use |
165; 134; 103; 109 | — |
| SECONDARY Syringe Service Program (SSP) Use |
223; 208; 45; 35 | — |
| SECONDARY Naloxone Overdose Kit |
164; 157; 104; 86 | — |
| SECONDARY Injection Drug Use |
108; 85; 160; 158 | — |
| SECONDARY Recent Drug Use |
42; 25; 225; 217 | — |
| SECONDARY Sharing Injection Equipment |
202; 175; 21; 23; 45; 45 | — |
| SECONDARY Non-fatal Overdose |
230; 210; 38; 33 | — |
| SECONDARY Emergency Department (ED) Use |
166; 144; 102; 99 | — |
| SECONDARY HIV Seroconversion |
236; 210; 1; 1 | — |
| SECONDARY HCV Seroconversion |
87; 105; 1; 6 | — |
| SECONDARY Mortality Rate |
268; 243; 4; 7 | — |
Eligibility Criteria
Inclusion Criteria
- If HIV-positive: report history of injection drug use
- If HIV-negative: injected drugs ≥ 4 days in the last 30 days or shared a needle or syringe in the last 6 months
Exclusion Criteria
- Not competent to provide written informed consent
- Not willing or able to provide a blood specimen
Data sourced from ClinicalTrials.gov (NCT03567174). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.